PSYCHIATRY, INCLUDING PSYCHEDELIC, CLINICAL TRIALS SITE OPENS IN PRIMARY CARE SETTING Novel therapies drive demand for new Paratus Clinical site
With
Megan Morrison,
Chief Executive Officer, Paratus Clinical
Professor Paul Fitzgerald,
Principal Investigator, Paratus Clinical &
Head of School of Medicine and Psychology, Australian National University
Bernadette Fitzgibbon
Director of Psychiatry Research, Paratus Clinical &
Associate Professor, Australian National University
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Melbourne | August 2025
Over the past decade, Paratus has been involved in over 200 clinical trials across 4 clinical site locations. Now a fifth site, the newly opened Melbourne site will cater to both primary care and psychiatry, specifically designed for psychedelic studies.
The new Melbourne site will be a focused on primary care studies specifically expanding access to psychiatric research, a growing area of unmet need. Australian Health Journal met with 3 recent hires brought in to support clinical trials across the organisation and in psychiatry in Melbourne.
– Megan Morrison, the recently appointed CEO of Paratus Clinical has 24 years of clinical research experience, industry knowledge and leadership, having worked across sponsor, CRO, and now site-side roles.
– Professor Paul Fitzgerald, the Director of the Australian National University School of Medicine and Psychology, provides senior academic leadership at Paratus Clinical as the Principal Investigator. Professor Fitzgerald is a renowned psychiatrist and researcher with over 25 years of experience leading clinical trials focused on psychiatric disorders. His pioneering work includes the development and evaluation of innovative treatments such as neurostimulation therapies (like transcranial magnetic stimulation) and novel pharmacological approaches. He plays a central role in trials in pharmacological-assisted psychotherapy and psychedelic compounds.
With extensive experience in conducting clinical research in psychiatry, Fitzgerald mentors the trial staff and ensures the integrity of the research protocols.
– Bernadette Fitzgibbon, the Director of Psychiatry Research at Paratus Clinical and Associate Professor at the Australian National University, has two decades experience in clinical research. She previously served as Deputy Director of the Monarch Research Institute and is affiliated with both Monash University and the Australian National University, contributing to national research efforts across psychiatry and psychology. She will collaborate closely with Professor Fitzgerald in running clinical trials in Melbourne.
Talking to Australian Health Journal, both Fitzgerald and Fitzgibbon highlight the growing need for innovative treatments in mental health, one which Paratus aims to address through a focused approach to psychiatric research.
Source: Adapted from transcript and Paratus Clinical news posts
You Might also like
-
Cardinal Health brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.
-
Confronting picture of growing women’s health crisis in uterine cancers
Uterine cancers have become Australia’s fastest-growing women’s cancer, with incidence doubling over the past 25 years and projected to continue to surge. Without immediate action, more than 44,000 women are expected to be diagnosed by 2035, and 8,900 will lose their lives to the disease.
Released November 2025, Australia’s first State of the Nation: Uterine Cancers in Australia 2025 report by the Australia New Zealand Gynaecological Oncology Group (ANZGOG), reveals a confronting picture of a growing women’s health crisis that has gone largely unseen and one that now requires immediate, coordinated national action.
-
Gavin Fox-Smith talks Medical Technology
Former Johnson & Johnson ANZ Managing Director, Gavin Fox-Smith on working in large & small MedTech companies